IO 102

Drug Profile

IO 102

Alternative Names: IDOlong; IO102

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Herlev Hospital; IO Biotech
  • Class Antineoplastics; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 12 Oct 2017 Phase-II clinical trials in Malignant melanoma (Parenteral)
  • 31 Aug 2016 Adverse event data from a phase I trial in Malignant melanoma released by IO Biotech
  • 01 Feb 2014 Phase-I clinical trials in Malignant melanoma (Metastatic disease, Late-stage disease, Combination therapy) in Denmark (Parenteral) (NCT02077114)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top